Articles

Have you ever asked ChatGPT to create a bio on yourself? Was it spot-on? Somewhat accurate? Total fiction? ChatGPT and similar programs, such as Google’s Med-PaLM 2 and Bard, and Microsoft’s Bing Chat, are generative artificial intelligence (AI) programs that use large language models to respond to prompts.

Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.”

Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results from the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting.

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial.

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.

Cancer researchers continue to make progress in developing tests using liquid biopsies that could complement and even serve as an alternative to traditional tissue biopsies.

Artificial intelligence (AI)-powered medical treatment options are on the rise and have the potential to improve diagnostic accuracy, but a new study led by University of Arizona Health Sciences researchers found that approximately 52% of participants would choose a human doctor rather than AI for diagnosis and treatment.

On June 15, 2023, the FDA accelerated the approval of glofitamab-gxbm (Columvi; Genentech), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥2 lines of systemic therapy.

On May 19, 2023, the FDA accelerated the approval of epcoritamab-bysp (Epkinly; Genmab US), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma after ≥2 lines of systemic therapy.

On August 2, 2023, the FDA approved a new indication for trifluridine and tipiracil (Lonsurf; Taiho Oncology), in combination with bevacizumab (Avastin), for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor biologic therapy; and if RAS wild-type, an anti–epidermal growth factor receptor therapy.